



Dicerna Pharmaceuticals  
Investor Relations Department  
87 Cambridgepark Drive  
Cambridge, MA 02140  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: DRNA

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 3.23                       |
| Trade Time:   | 4:00 PM ET<br>May 23, 2017 |
| Change:       | -0.05  (-1.524%)           |
| Day Range     | 3.21 - 3.38                |
| 52-Week Range | 2.42 - 6.10                |
| Volume        | 38,276                     |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The Company is using its proprietary GalXC RNAi technology platform to build a broad pipeline in these therapeutic areas.

[Dicerna Corporate Fact Sheet\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- May 8, 2017*  
[Dicerna Reports First Quarter 2017 Financial and Operational Results and Provides Corporate Update](#)
- May 1, 2017*  
[Dicerna to Report First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017](#)
- Apr 12, 2017*  
[Dicerna Announces Closing of \\$70 Million Convertible Preferred Stock Financing](#)
- Mar 30, 2017*  
[Dicerna Reports Fourth Quarter and Full Year 2016 Financial and Operational Results](#)
- Mar 30, 2017*  
[Dicerna Secures \\$70 Million in Convertible Preferred Stock Financing](#)

## Financials [\[ View all \]](#)

- Mar 30, 2017*  
[Annual Report \(10-K\)](#)
- May 23, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016*  
[Quarterly Report \(10-Q\)](#)